Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus

NEW YORK, July 1, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Gilead Sciences Inc. (NASDAQ: GILD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), QLT Inc. (NASDAQ: QLTI) and Agenus Inc. (NASDAQ: AGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4298-100free.

--
Pfizer Inc. Analyst Notes
On June 26, 2014, the Board of Directors of Pfizer Inc. (Pfizer) declared Q3 2014 dividend of $0.26 per share on the Company's common stock. According to the Company, the 303rd consecutive quarterly dividend is payable on September 3, 2014, to shareholders of record as of the close of business on August 1, 2014. The full analyst notes on Pfizer are available to download free of charge at:

http://www.analystsreview.com/Jul-01-2014/PFE/report.pdf

--
Gilead Sciences Inc. Analyst Notes
On June 26, 2014, Gilead Sciences Inc.'s (Gilead) stock went up by 0.46%, closing at $82.18. For the past three day trading period, Gilead's stock increased by 1.71% compared to the Nasdaq Composite which moved up 0.24% during the same trading period. The full analyst notes on Gilead are available to download free of charge at:

http://www.analystsreview.com/Jul-01-2014/GILD/report.pdf

--
Pacira Pharmaceuticals Inc. Analyst Notes
On June 26, 2014, Pacira Pharmaceuticals Inc. (Pacira) announced results from a pooled analysis of IMPROVE, a series of open-label prospective, Phase 4 clinical studies that were designed to compare postsurgical narcotic use and health economic outcomes associated with EXPAREL® as a foundation of a multimodal analgesic regimen versus a standard opioid-based pain management regimen. According to the Company, the analysis, which was published in the June 2014 issue of Journal of Pain Research, concluded that EXPAREL-based multimodal regimen was associated with significant reductions in opioid consumption, incidence of opioid-related adverse events (ORAEs), length of hospital stay and total hospital costs, in comparison to the current standard of care. Company President, CEO and Chairman, Dave Stack, stated, "The completion of our IMPROVE Phase 4 program marks an important milestone for the company and EXPAREL." The full analyst notes on Pacira are available to download free of charge at:

http://www.analystsreview.com/Jul-01-2014/PCRX/report.pdf

--
QLT Inc. Analyst Notes
On June 26, 2014, QLT Inc. (QLT) and Auxilium Pharmaceuticals, Inc. (Auxilium) announced a definitive agreement under which Auxilium plans to merge with QLT. QLT stated that under the agreement, a wholly-owned subsidiary of QLT will be merged with and into Auxilium and the Company will renamed to New Auxilium, and will remain incorporated in British Columbia, Canada. The Company added that current Auxilium shareholders will receive c.3.14 QLT shares for each Auxilium share, subject to certain adjustments while for QLT shareholders, the transaction represents a 25% premium, based on a calculation of the closing NASDAQ stock prices of Auxilium and QLT as of the last trading day prior to the announcement of the merger, June 25, 2014. QLT Chairman, Jason Aryeh, commented, "We believe that this is an excellent transaction for QLT shareholders and provides them with the opportunity to benefit from the potential upside of the combined company." The full analyst notes on QLT are available to download free of charge at:

http://www.analystsreview.com/Jul-01-2014/QLTI/report.pdf

--
Agenus Inc. Analyst Notes
On June 26, 2014, Agenus Inc. (Agenus) announced the Company's Phase 2 results for HerpV- a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 (HSV-2) and it contains a defined mixture of peptides representing HSV-2 antigens plus Agenus' QS-21 Stimulon® adjuvant. Additionally, the Company stated that in Phase 2 study, majority of the patients showed an immune response to the HSV antigens after a series of vaccinations and a booster dose at six months. Agenus Chief Scientific Officer, Robert Stein, M.D., Ph.D., commented, "We are pleased that the cellular immune response observed with HerpV vaccination is associated with a significant reduction in viral replication in the genital tract. The fact that our vaccine contains multiple HSV- 2 antigens may contribute to its desired effects. We look forward to advancing discussions with potential partners to take this program into the next phase of clinical research." The full analyst notes on Agenus are available to download free of charge at:

http://www.analystsreview.com/Jul-01-2014/AGEN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED